Letztes “update” :
19/11/2024
Antikrebsmittel   Bleomycin sulfate  
Injektion
Stabilität der Lösung Gemengestabilität Stabilitätbeeinflussende Faktoren Kompatibilitäten Applikationsart Literaturverzeichnis pdf
   Chemische Struktur  

Handelsmarke   Handelsmarke     

Handelsnamen sind als beispielhaft anzusehen. Sonstige Bestandteile können je nach Hersteller oder Land verschieden sein

Bileco Argentinien
Blemisin Türkei
Blenamax Australien, Kolumbien, Malaysia
Blenoxane Australien, Vereinigte Staaten von Amerika
Bleo-Kyowa Großbritannien
Bleocell Deutschland
Bleocin Griechenland, Japan, Malaysia, Peru, Polen, Portugal, Saudi-Arabien, Türkei, Ungarn, Vereinigte Arabische Emirate
Bleocip Ägypten, Venezuela
Bleocris Argentinien, Chile, Peru
Bleolem Kolumbien, Mexiko
Bleomax Mexiko
Bleomedac Deutschland
Bleomicina Chile, Ecuador, Italien, Kolumbien, Mexiko, Peru, Spanien
Bleomycin Australien, Dänemark, Deutschland, Finnland, Großbritannien, Iran, Island, Niederlande, Norwegen, Österreich, Polen, Rumänien, Schweden, Ungarn, Vereinigte Staaten von Amerika
Bleomycine Belgien, Frankreich, Irland, Kanada, Luxemburg, Malaysia, Marokko, Neuseeland, Schweiz, Tunesien
Bleomycine A Dänemark
Bleomycinum Deutschland
Bleozen Peru
Blexit Chile
Blocamicina Argentinien
Bloicin Ägypten, Peru
Blomindex Mexiko
Blucin Marokko
DBL Bleomycin Malaysia, Neuseeland
Ifabec Mexiko
Lyoble Peru
Nikableocina Chile
Oncobleocin Kolumbien
Literaturverzeichnis   Injektion   Literaturverzeichnis : Bleomycin sulfate  
Typ Veröffentlichung
3 Zeitung Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81 Zeitung Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Zeitung Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 Zeitung Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 Zeitung Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Zeitung Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 Zeitung Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248 Zeitung Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 Zeitung Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Zeitung Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
252 Zeitung Koberda M, Zieske PA, Raghavan NV, Payton RJ.
Stability of bleomycin sulfate reconstituted in 5% dextrose injection or 0.9% sodium chloride injection stored in glass vials or polyvinyl chloride containers.
Am J Hosp Pharm 1990 ; 47: 2528-2529.
307 Zeitung Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 Zeitung Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Zeitung Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
492 Zeitung Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
905 Zeitung Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
1410 Zeitung Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1423 Zeitung Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
3128 Labor Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
Prostrakan 2013
3420 Zeitung El Kateb N, Chaussard M, Bellenger P, Petit A, Faure P.
Stability of an extemporaneously prepared bleomycin-lidocaine-epinephrine intradermal admixture used in dermatology
J Oncol Pharm Practice 2014 ; 21, 3: 178-187.
3578 Labor Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011
3644 Labor Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3646 Labor Bléomycine sulfate (Bléomycine Bellon®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2013
4154 Labor Bleomycin sulfate- Summary of Product Characteristics
Accord Health Care 2018
4471 Labor Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019
Kyowa Kirin Pharma 2019

  Mentions Légales